|
1
|
Subramanian VS, Stephenson AJ, Goldfarb
DA, Fergany AF, Novick AC and Krishnamurthi V: Utility of
preoperative renal artery embolization for management of renal
tumors with inferior vena caval thrombi. Urology. 74:154–159. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Clark PE: The role of VHL in clear-cell
renal cell carcinoma and its relation to targeted therapy. Kidney
Int. 76:939–945. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bultitude MF: Campbell-Walsh Urology. 10th
edition. BJU International; New York, NY: 2012
|
|
5
|
Guo K, Searfoss G, Krolikowski D, Pagnoni
M, Franks C, Clark K, Yu KT, Jaye M and Ivashchenko Y: Hypoxia
induces the expression of the pro-apoptotic gene BNIP3. Cell Death
Differ. 8:367–376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gunaratnam L, Morley M, Franovic A, de
Paulsen N, Mekhail K, Parolin DA, Nakamura E, Lorimer IA and Lee S:
Hypoxia inducible factor activates the transforming growth
factor-alpha/epidermal growth factor receptor growth stimulatory
pathway in VHL(−/−) renal cell carcinoma cells. J Biol Chem.
278:44966–44974. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yasuda M, Theodorakis P, Subramanian T and
Chinnadurai G: Adenovirus E1B-19K/BCL-2 interacting protein BNIP3
contains a BH3 domain and a mitochondrial targeting sequence. J
Biol Chem. 273:12415–12421. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kothari S, Cizeau J, McMillan-Ward E,
Israels SJ, Bailes M, Ens K, Kirshenbaum LA and Gibson SB: BNIP3
plays a role in hypoxic cell death in human epithelial cells that
is inhibited by growth factors EGF and IGF. Oncogene. 22:4734–4744.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Höckel M and Vaupel P: Tumor hypoxia:
Definitions and current clinical, biologic, and molecular aspects.
J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vaupel P, Kelleher DK and Höckel M: Oxygen
status of malignant tumors: Pathogenesis of hypoxia and
significance for tumor therapy. Semin Oncol. 28(Suppl 8): 29–35.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matak D, Brodaczewska KK, Lipiec M,
Szymanski Ł, Szczylik C and Czarnecka AM: Colony, hanging drop, and
methylcellulose three dimensional hypoxic growth optimization of
renal cell carcinoma cell lines. Cytotechnology. 69:565–578. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parks SK, Cormerais Y and Pouysségur J:
Hypoxia and cellular metabolism in tumour pathophysiology. J
Physiol. 595:2439–2450. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo L, Xiong ZB, Zeng H, Chen N, Chen XQ,
Zhang P and Li X: Expression of BNIP3 and its correlations to
HIF-1alpha and VEGF in clear cell renal cell carcinoma. Sichuan Da
Xue Xue Bao Yi Xue Ban. 43:79–82. 2012.In Chinese. PubMed/NCBI
|
|
14
|
Ding Y, Yu L, Li M, Liu L and Zhong H:
Establishment and biological characteristics of human renal
granular cell carcinoma cell line (GRC-1). Chin J Urol. 16:3–6.
1995.In Chinese.
|
|
15
|
Jiang Z, Liu X, Chang K, Liu X and Xiong
J: Allyl isothiocyanate inhibits the proliferation of renal
carcinoma cell line GRC-1 by inducing an imbalance between Bcl2 and
Bax. Med Sci Monit. 22:4283–4288. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun X, Lou L, Zhong K and Wan L:
MicroRNA-451 regulates chemoresistance in renal cell carcinoma by
targeting ATF-2 gene. Exp Biol Med (Maywood). Jan 1–2017.Epub ahead
of print. View Article : Google Scholar
|
|
17
|
Okami J, Simeone DM and Logsdon CD:
Silencing of the hypoxia-inducible cell death protein BNIP3 in
pancreatic cancer. Cancer Res. 64:5338–5346. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bacon AL, Fox S, Turley H and Harris AL:
Selective silencing of the hypoxia-inducible factor 1 target gene
BNIP3 by histone deacetylation and methylation in colorectal
cancer. Oncogene. 26:132–141. 2007. View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Murai M, Toyota M, Suzuki H, Satoh A,
Sasaki Y, Akino K, Ueno M, Takahashi F, Kusano M, Mita H, et al:
Aberrant methylation and silencing of the BNIP3 gene in colorectal
and gastric cancer. Clin Cancer Res. 11:1021–1027. 2005.PubMed/NCBI
|
|
21
|
Chinnadurai G, Vijayalingam S and Gibson
SB: BNIP3 subfamily BH3-only proteins: Mitochondrial stress sensors
in normal and pathological functions. Oncogene. 27(Suppl 1):
S114–S127. 2008. View Article : Google Scholar
|
|
22
|
Ryter SW, Mizumura K and Choi AM: The
impact of autophagy on cell death modalities. Int J Cell Biol.
2014.502676:2014.
|
|
23
|
Jing K and Lim K: Why is autophagy
important in human diseases? Exp Mol Med. 44:69–72. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gump JM and Thorburn A: Autophagy and
apoptosis: What is the connection? Trends Cell Biol. 21:387–392.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su M, Mei Y and Sinha S: Role of the
Crosstalk between Autophagy and Apoptosis in Cancer. J Oncol.
2013.102735:2013.
|
|
26
|
Mariño G, Niso-Santano M, Baehrecke EH and
Kroemer G: Self-consumption: The interplay of autophagy and
apoptosis. Nat Rev Mol Cell Biol. 15:81–94. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Azad MB and Gibson SB: Role of BNIP3 in
proliferation and hypoxia-induced autophagy: Implications for
personalized cancer therapies. Ann N Y Acad Sci. 1210:8–16. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Burton TR and Gibson SB: The role of Bcl-2
family member BNIP3 in cell death and disease: NIPping at the heels
of cell death. Cell Death Differ. 16:515–523. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giatromanolaki A, Koukourakis MI, Gatter
KC, Harris AL and Sivridis E: BNIP3 expression in endometrial
cancer relates to active hypoxia inducible factor 1alpha pathway
and prognosis. J Clin Pathol. 61:217–220. 2008. View Article : Google Scholar
|
|
30
|
Giatromanolaki A, Koukourakis MI, Sowter
HM, Sivridis E, Gibson S, Gatter KC and Harris AL: BNIP3 expression
is linked with hypoxia-regulated protein expression and with poor
prognosis in non small cell lung cancer. Clin Cancer Res.
10:5566–5571. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lukashova-v Zangen I, Kneitz S, Monoranu
CM, Rutkowski S, Hinkes B, Vince GH, Huang B and Roggendorf W:
Ependymoma gene expression profiles associated with histological
subtype, proliferation, and patient survival. Acta Neuropathol.
113:325–337. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Erkan M, Kleeff J, Esposito I, Giese T,
Ketterer K, Büchler MW, Giese NA and Friess H: Loss of BNIP3
expression is a late event in pancreatic cancer contributing to
chemoresistance and worsened prognosis. Oncogene. 24:4421–4432.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tang H, Liu YJ, Liu M and Li X:
Establishment and gene analysis of an oxaliplatin-resistant colon
cancer cell line THC8307/L-OHP. Anticancer Drugs. 18:633–639. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de Angelis PM, Fjell B, Kravik KL, Haug T,
Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E and Stokke
T: Molecular characterizations of derivatives of HCT116 colorectal
cancer cells that are resistant to the chemotherapeutic agent
5-fluorouracil. Int J Oncol. 24:1279–1288. 2004.PubMed/NCBI
|
|
35
|
Jacobsen J, Grankvist K, Rasmuson T, Bergh
A, Landberg G and Ljungberg B: Expression of vascular endothelial
growth factor protein in human renal cell carcinoma. BJU Int.
93:297–302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gardiner-Garden M and Frommer M: CpG
islands in vertebrate genomes. J Mol Biol. 196:261–282. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bird AP: CpG-rich islands and the function
of DNA methylation. Nature. 321:209–213. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Graff JR, Herman JG, Myöhänen S, Baylin SB
and Vertino PM: Mapping patterns of CpG island methylation in
normal and neoplastic cells implicates both upstream and downstream
regions in de novo methylation. J Biol Chem. 272:22322–22329. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Herman JG, Umar A, Polyak K, Graff JR,
Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW,
et al: Incidence and functional consequences of hMLH1 promoter
hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA.
95:6870–6875. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Murai M, Toyota M, Satoh A, Suzuki H,
Akino K, Mita H, Sasaki Y, Ishida T, Shen L, Garcia-Manero G, et
al: Aberrant DNA methylation associated with silencing BNIP3 gene
expression in haematopoietic tumours. Br J Cancer. 92:1165–1172.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cleven AHG, Spiertz A, Wouters B, van
Engeland M and De Bruine A: Stromal expression of RIF 2A correlates
with BNIP3 promoter hypermethylation and overall patient survival
in colorectal carcinomas. Cell Oncol. 29:1272007.
|
|
42
|
Abe T, Toyota M, Suzuki H, Murai M, Akino
K, Ueno M, Nojima M, Yawata A, Miyakawa H, Suga T, et al:
Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes
pancreatic cancer cells to hypoxia-mediated cell death. J
Gastroenterol. 40:504–510. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Eckschlager T, Plch J, Stiborova M and
Hrabeta J: Histone Deacetylase Inhibitors as Anticancer Drugs. Int
J Mol Sci. 18:pii: E1414. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park KC, Heo JH, Jeon JY, Choi HJ, Jo AR,
Kim SW, Kwon HJ, Hong SJ and Han KS: The novel histone deacetylase
inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits
potent antitumor activity due to cytochrome-c-release-mediated
apoptosis in renal cell carcinoma cells. BMC Cancer. 15:192015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Park WH, Jung CW, Park JO, Kim K, Kim WS,
Im YH, Lee MH, Kang WK and Park K: Trichostatin inhibits the growth
of ACHN renal cell carcinoma cells via cell cycle arrest in
association with p27, or apoptosis. Int J Oncol. 22:1129–1134.
2003.PubMed/NCBI
|
|
46
|
Nagata Y and Todokoro K: Requirement of
activation of JNK and p38 for environmental stress-induced
erythroid differentiation and apoptosis and of inhibition of ERK
for apoptosis. Blood. 94:853–863. 1999.PubMed/NCBI
|
|
47
|
Yang Q, Wang Y, Pan X, Ye J, Gan S, Qu F,
Chen L, Chu C, Gao Y and Cui X: Frizzled 8 promotes the cell
proliferation and metastasis of renal cell carcinoma. Oncotarget.
8:78989–79002. 2017.PubMed/NCBI
|
|
48
|
Santos N, Wenger JB, Havre P, Liu Y, Dagan
R, Imanirad I, Ivey AM, Zlotecki RA, Algood CB, Gilbert SM, et al:
Combination therapy for renal cell cancer: What are possible
options? Oncology. 81:220–229. 2011. View Article : Google Scholar : PubMed/NCBI
|
